Orexin-A vs DSIP

Orexin-A is a hypothalamic neuropeptide that stabilises wakefulness — its loss causes narcolepsy. DSIP was proposed to promote sleep but lacks a defined receptor.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

Orexin-A

A hypothalamic neuropeptide that stabilises wakefulness; its loss causes narcolepsy type 1.

BEST STUDIED FOR

Nootropic & neuro

Read the cited profile →

🧪

DSIP

A nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) isolated in 1977 from rabbit cerebral venous blood during studies of sleep.

BEST STUDIED FOR

Nootropic & neuro

Read the cited profile →

SIDE BY SIDE

	Orexin-A	DSIP
The key difference	Wake-promoting neuropeptide	Proposed sleep-promoting peptide
Class	Nootropic & neuro	Nootropic & neuro
Mechanism	Orexin-A activates OX1R and OX2R receptors, driving arousal, attention and sympathetic tone.	DSIP was named for enhancing slow-wave (delta) EEG activity after brain infusion in rabbits.
Status	Research peptide; intranasal pilot studies in humans and animal models of cognitive dysfunction.	Studied in the 1980s in small human sleep studies; no approved medicine and little modern research.
Reported safety signals	A pilot human study found intranasal orexin A modulated sympathetic vascular tone; no long-term data.	Older small studies reported no major issues; data are too limited to characterise safety.
A key study	Reviews orexin-A/B and their two receptors in sleep–wake regulation. (Front Neurol Neurosci 2021, PMID 34052813)	The isolation paper: a peptide enhancing delta EEG after brain infusion in rabbits, with its amino-acid sequence. (Proc Natl Acad Sci U S A 1977, PMID 265572)

WHEN TO RESEARCH WHICH

Orexin-A is well-validated; DSIP remains unresolved. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Orexin-A] Hypocretin/Orexin Receptor Pharmacology and Sleep Phases — Front Neurol Neurosci 2021. PMID 34052813
[Orexin-A] Intranasal orexin A modulates sympathetic vascular tone: a pilot study in healthy male humans — J Neurophysiol 2022. PMID 35044844
[Orexin-A] Effects of Intranasal Orexin-A (Hypocretin-1) Administration on Neuronal Activation, Neurochemistry, and Attention in Aged Rats — Front Aging Neurosci 2019. PMID 32038222
[DSIP] Characterization of a delta-electroencephalogram (-sleep)-inducing peptide — Proc Natl Acad Sci U S A 1977. PMID 265572
[DSIP] Delta sleep-inducing peptide (DSIP): a still unresolved riddle — J Neurochem 2006. PMID 16539679
[DSIP] DSIP in sleep disturbances — Eur Neurol 1986. PMID 3758119

FREQUENTLY ASKED

What is the difference between Orexin-A and DSIP?

Orexin-A is a hypothalamic neuropeptide that stabilises wakefulness — its loss causes narcolepsy. DSIP was proposed to promote sleep but lacks a defined receptor.

What is the regulatory status of Orexin-A and DSIP?

Orexin-A: Research peptide; intranasal pilot studies in humans and animal models of cognitive dysfunction. DSIP: Studied in the 1980s in small human sleep studies; no approved medicine and little modern research.

What safety signals have been reported?

Orexin-A: A pilot human study found intranasal orexin A modulated sympathetic vascular tone; no long-term data. DSIP: Older small studies reported no major issues; data are too limited to characterise safety.

Which studies is this comparison based on?

For Orexin-A: “Hypocretin/Orexin Receptor Pharmacology and Sleep Phases” (PMID 34052813); “Intranasal orexin A modulates sympathetic vascular tone: a pilot study in healthy male humans” (PMID 35044844); “Effects of Intranasal Orexin-A (Hypocretin-1) Administration on Neuronal Activation, Neurochemistry, and Attention in Aged Rats” (PMID 32038222). For DSIP: “Characterization of a delta-electroencephalogram (-sleep)-inducing peptide” (PMID 265572); “Delta sleep-inducing peptide (DSIP): a still unresolved riddle” (PMID 16539679); “DSIP in sleep disturbances” (PMID 3758119).